Nicola Campbell, Ph.D., joined Sofinnova Ventures in 2004 to focus on early-stage investment opportunities in the sectors of drug discovery and pharmaceutical & biologic development. Her well-rounded background makes her a natural asset to our team—and to our portfolio companies. She has a terrific track record in the life science industry as a venture capitalist, a business development executive and an immunologist.

Previously, Nicola worked for BA Venture Partners, where she focused on mid-stage investment opportunities in drug discovery and product-based companies, and Burrill & Company, a life science merchant banking firm focusing on biotechnology venture capital.

Prior to joining the venture community, Nicola held both business development and scientific roles at Genentech. She developed strategic partnerships with Actelion and Gene Logic, among others, and was a member of the Cardiovascular Therapeutic Area Team which was responsible for the strategic vision of that franchise. She initially joined Genentech as an immunologist in the research department.

Nicola received her Ph.D. in Molecular and Cellular Immunology from Mount Sinai Medical Center, during which she was a recipient of the American Gastroenterology Association’s Outstanding Research Award. She completed her MS in Medical Sciences from the Mount Sinai School of Medicine, and received her BS in Human Biology from the University of Guelph in Ontario, Canada, where she was awarded the Dean’s Scholarship for Academic Excellence.

Nicola can be reached at (415) 228-3398 or nicola@sofinnova.com.

© 1997-2007 Sofinnova Ventures, Inc.
All rights reserved.